Castle Biosciences Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Castle Biosciences (CSTL) reported strong third-quarter results for 2026, highlighted by a 24% increase in total revenue to $102.9 million. This growth was primarily driven by the TissueCypher test segment, which saw a 47% volume increase to 15,574 reports. Due to this momentum and improved average selling prices, management raised its full-year revenue guidance to a range of $385 million to $395 million. The company demonstrated operational efficiency with an Adjusted EBITDA of $12.7 million and a healthy cash position of $278 million in cash and marketable securities. While the company reported a net loss of $4.1 million per share, driven partly by noncash stock-based compensation, its adjusted gross margin remained stable at 77%. Management remains focused on scaling TissueCypher while navigating regulatory and coverage landscapes for other products like DecisionDx-SCC.
Topics: cash flow EBITDA guidance increase revenue growth test volume